InfuSystem reports record 2024 revenue of $134.9M, +7% YoY; Adj EBITDA +13% to $25.3M; guides 2025 revenue growth 8-10%

InfuSystem Holdings, Inc

Q4 net revenues $33.8M (+7% YoY); net income $0.9M ($0.04 EPS) vs $0.1M prior year.
Full year adj EBITDA $25.3M (+13%); operating cash flow $20.5M (+82%).
Patient Services rev $80.4M (+5%), Device Solutions $54.5M (+11%) for full year.
2025 guidance: revenue growth 8-10%, adj EBITDA margin above 18.8%.
Repurchased $1.2M in 2024 and ~$2.4M in Q1 2025; net debt down $5.5M to $23.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.